CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02616 CSTONE PHARMA-B

Closed Easter Monday 04-17 16:08:09

2.510

+0.010

+0.40%

High2.550	Low2.460	Vol2.51M
Open2.490	D1 Closing2.500	Amplitude3.60%
Mkt Cap3.42B	Tradable Cap3.42B	Total Shares1.36B
T/O6.29M	T/O Rate0.18%	Tradable Shares1.36B
P/B8.85	ROE-22.23%	EPS-0.08
52wk High3.890	52wk Low0.810	P/E-33.04
Dividend0.00	Div.Yield0.00	ROA-3.90%

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"CSTONE PHARMA-B","latestPrice":2.51,"timestamp":1744877289030,"preClose":2.5,"halted":0,"volume":2509500,"delay":0,"floatShares":1364000000,"shares":1364000000,"eps":-0.07597203381976247,"marketStatus":"Closed Easter Monday","change":0.01,"latestTime":"04-17 16:08:09","open":2.49,"high":2.55,"low":2.46,"amount":6286548,"amplitude":0.036,"askPrice":2.53,"askSize":6000,"bidPrice":2.51,"bidSize":25000,"shortable":0,"etf":0,"ttmEps":-0.07597203381976247,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":2.5,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":0.3006325322873028,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2526339749","title":"CStone Pharmaceuticals CEO Boosts Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=2526339749","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526339749?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 16:46","pubTimestamp":1744188396,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  Chief Executive Officer Jianxin Yang increased his holding in the drug company by 560,000 shares, according to a Wednesday filing with the Hong Kong bourse.Yang purchased the shares at a price ranging from HK$2.26 to HK$3.29 apiece, the filing said.Since beginning in his role as CEO, Yang has bought 10,359,000 shares, or 5.46% of the total shareholding of CStone.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2526381021","title":"BRIEF-Cstone Pharmaceuticals Announces Further Increase In Shareholding By CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2526381021","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526381021?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 15:01","pubTimestamp":1744182101,"startTime":"0","endTime":"0","summary":"BRIEF-Cstone Pharmaceuticals Announces Further Increase In Shareholding By CEO April 9  - CStone Pharmaceuticals 2616.HK:FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTORCEO PURCHASED 560,000 SHARES FROM APRIL 2 TO 7 WITH PURCHASE PRICE PER SHARE RANGING FROM HKD2.26 TO HKD3.29Further company coverage: 2616.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN05L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2526802897","title":"CStone Pharmaceuticals - Further Increase in Shareholding by CEO and Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2526802897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526802897?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 12:28","pubTimestamp":1744172937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN05L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2526780233","title":"CStone Pharmaceuticals - CEO Purchased 560,000 Shares From April 2 to 7 With Purchase Price per Share Ranging From HKD2.26 to HKD3.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2526780233","media":"THOMSON REUTERS","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526780233?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 12:28","pubTimestamp":1744172937,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN05L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CStone Pharmaceuticals - CEO Purchased 560,000 Shares From April 2 to 7 With Purchase Price per Share Ranging From HKD2.26 to HKD3.29","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"1113149057","title":"Stock Track | CStone Pharma Plummets 5.20% as 2024 Earnings Miss Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1113149057","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113149057?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 10:10","pubTimestamp":1743646249,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  saw its stock price plummet 5.20% in intraday trading on Thursday following the release of its full-year 2024 financial results, which fell short of analyst expectations. The biopharmaceutical company's disappointing performance has sparked concern among investors, leading to a significant sell-off.The earnings report revealed that CStone's revenue for the fiscal year 2024 dropped 12% compared to the previous year, reaching CN407.2 million. This figure missed analyst esti","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | CStone Pharma Plummets 5.20% as 2024 Earnings Miss Expectations","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02616"],"gpt_icon":0},{"id":"2524353473","title":"CStone Pharmaceuticals Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2524353473","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524353473?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 08:58","pubTimestamp":1743641915,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( HKG:2616 ) Full Year 2024 Results Key Financial Results Revenue: CN¥407.2m (down 12% from FY...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-full-year-2024-earnings-misses-expect","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02616"],"gpt_icon":0},{"id":"2524108018","title":"BUZZ-CStone Pharmaceuticals hits 5-week low on discounted share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2524108018","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524108018?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 09:54","pubTimestamp":1743558885,"startTime":"0","endTime":"0","summary":"BUZZ-CStone Pharmaceuticals hits 5-week low on discounted share sale** CStone Pharmaceuticals 2616.HK slides 13% to HK$3, lowest since February 25** Stock set for biggest one-day pct decline since March 7, 2024; top pct loser on Hong Kong bourse** Chinese biopharma developer plans to sell 80 mln new shares to third party investors to raise HK$234.6 mln  for R&D and general corporate purposes** Says shares will be issued at HK$2.933, representing ~15% discount to Tuesday's close of HK$3.45** Stock gains 30.4% YTD    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nL2N3QG01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"1151905054","title":"Stock Track | CStone Pharmaceuticals Plummets 8.70% on Share Placement Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1151905054","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151905054?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 09:33","pubTimestamp":1743557591,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  saw its stock price plummet by 8.70% in pre-market trading on Wednesday following the company's announcement of a significant share placement plan. The biopharmaceutical firm, focused on developing and commercializing innovative immuno-oncology and precision medicines, revealed its intention to issue up to 80 million new shares to at least six investors.According to the company's filing with the Hong Kong Stock Exchange, the placement price is set at HK$2.933 per share. T","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | CStone Pharmaceuticals Plummets 8.70% on Share Placement Announcement","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02616"],"gpt_icon":0},{"id":"2524617235","title":"CStone Pharmaceuticals to Raise HK$232 Million from Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524617235","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524617235?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 09:10","pubTimestamp":1743556211,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  plans to issue up to 80 million shares to at least six investors under a placement deal at HK$2.933 apiece, according to a Wednesday filing with the Hong Kong bourse.The shares comprise 5.86% of the entire share capital of the drug company following completion.Net proceeds, estimated at HK$232.3 million, will be used for the development of cancer drugs and for other general corporate purposes.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2524179253","title":"BRIEF-Cstone Pharmaceuticals To Place Aggregate Of 80 Million Placing Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2524179253","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524179253?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 08:43","pubTimestamp":1743554613,"startTime":"0","endTime":"0","summary":"BRIEF-Cstone Pharmaceuticals To Place Aggregate Of 80 Million Placing SharesApril 2 (Reuters) - CStone Pharmaceuticals 2616.HK:TO PLACE AGGREGATE OF 80 MILLION PLACING SHARES AT HK$2.933 PER SHAREFurther company coverage: 2616.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2524175182","title":"CStone Pharmaceuticals - to Place Aggregate of 80 Mln Placing Shares at HK$2.933 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2524175182","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524175182?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 08:01","pubTimestamp":1743552093,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2522308806","title":"BRIEF-CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522308806","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522308806?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:39","pubTimestamp":1743079169,"startTime":"0","endTime":"0","summary":"BRIEF-CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business ProgressMarch 27 (Reuters) - CStone Pharmaceuticals 2616.HK:CSTONE PHARMACEUTICALS ANNOUNCES 2024 ANNUAL RESULTS AND RECE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6BQ3WC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2522747883","title":"CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522747883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522747883?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:55","pubTimestamp":1743076548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6BQ3WC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2522374205","title":"Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374205?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:55","pubTimestamp":1743076500,"startTime":"0","endTime":"0","summary":"-      Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.-          EU & UK: Approved for first-line treatment of stage IV non-small cell lung cancer ; stage III NSCLC new indication application submitted to EMA.-     Global Partnerships: Three strategic partnerships across 40+ countries, to accelerate global commercialization.-      Localized Production: Approved for localized manufacturing in China, enhancing cost efficiency.-      Commercial Collaboration: Partnered with Hengrui to expand market access in China.-      Leading Position: Top 2 globally in clinical development for ROR1-targeted ADCs.-      Preclinical Differentiation: Superior tumor suppression vs. benchmarked competitors; potential first-in-class/best-in-class IO backbone therapy.-      More than 9 Differentiated Candidates: Focus on first-in-class/best-in-class assets, including multispecific antibodies and ADCs, with global rights and broad therapeutic potential.SUZHOU, Ch","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823414478.USD","R","ADC","BK4232","LU2065732104.USD","BK4570","LU2294711713.HKD","BE","LU2463526074.USD","BK1574","BK4211","LU0444973449.USD","SITC","BK4182","BK4585","SOC","BK4213","BK4097","CDE","LU1815336760.USD","LU2357125470.USD","BK1161","ORR","BK4541","02616","BK4231","PRGS","BK4195","PFS","BK4588","BK4017","LU0476273544.USD","ASH","BK4022","LU2249611893.SGD","BK4210","LU0823414551.USD","LU0345780521.USD","LU2506951792.HKD","CPS","BK4109","LU0444971666.USD","LU0957808578.USD","CEE","HL","BK4080","BK4124","OS","LU1642822529.SGD"],"gpt_icon":0},{"id":"2522828341","title":"CStone Pharmaceuticals - Revenue Was RMB407.2 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522828341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522828341?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 16:32","pubTimestamp":1743064350,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA04P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2521796124","title":"CStone Seeks EU Approval for New Indication of Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521796124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521796124?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 16:28","pubTimestamp":1742804934,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (HKG:2616) submitted a Type II variation application to the European Medicines Agency (EMA) for a new indication of sugemalimab in stage III non-small cell lung cancer (NSCLC).T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2521780747","title":"CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage Iii Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521780747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521780747?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 08:15","pubTimestamp":1742775305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4F329W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2520181703","title":"CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181703","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181703?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 17:05","pubTimestamp":1742375154,"startTime":"0","endTime":"0","summary":"As global markets grapple with inflation concerns and trade policy uncertainties, investors are seeking opportunities that can navigate these challenges. Penny stocks, a term that may seem outdated, still represent an intriguing investment area for those interested in smaller or newer companies. These stocks can offer surprising value and potential for significant returns when backed by solid financial foundations.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/materials/szse-002721/beijing-kingee-culture-development-shares/news/cstone-pharmaceuticals-leads-our-top-3-global-penny-stock-pi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SGXZ58947870.SGD","LU0082770016.SGD","SG9999013460.SGD","SG9999016042.SGD","BK6065","LU0516422952.EUR","BK6504","LU0516422440.USD","SG9999004360.SGD","SG9999014484.SGD","SGXZ27511609.SGD","SG9999000343.SGD","BK7129","BK1574","LU1242518857.USD","SGXZ43160589.SGD","SG9999000475.SGD","LU0516423174.USD","LU1242518931.SGD","SGXZ24219693.SGD","LU0516422366.SGD","LU0164939612.USD","LU0516423091.SGD","SG9999013486.USD","SG9999003826.SGD","LU0979878070.USD","SG9999014492.USD","02616","LU0082770016.USD","LU0620787316.HKD","BK1161","SG9999013478.USD","BIS.AU"],"gpt_icon":1},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  submitted the Phase I-B trial application in Australia for its large B-cell lymphoma  drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate  that works with first-line standard-of-care  to diffuse large B-cell lymphoma , the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4080","BK1161","XJO.AU","XAO.AU","XKO.AU","BK1574","ADC","ADC.AU","BK4231","02616"],"gpt_icon":0},{"id":"2517976361","title":"CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976361?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 08:10","pubTimestamp":1741219803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA2T0MDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0866},{"period":"1month","weight":-0.3216},{"period":"3month","weight":0.162},{"period":"6month","weight":0.4261},{"period":"1year","weight":1.9186},{"period":"ytd","weight":0.0913}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.062298},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039956},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.10478},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.063703},{"month":5,"riseRate":0.4,"avgChangeRate":0.039766},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097121},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049356},{"month":8,"riseRate":0.333333,"avgChangeRate":0.010588},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033892},{"month":10,"riseRate":0.5,"avgChangeRate":0.015157},{"month":11,"riseRate":0.666667,"avgChangeRate":0.016123},{"month":12,"riseRate":0.5,"avgChangeRate":0.028191}],"exchange":"SEHK","name":"CSTONE PHARMA-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CSTONE PHARMA-B,02616,CSTONE PHARMA-B股票,CSTONE PHARMA-B股票老虎,CSTONE PHARMA-B股票老虎国际,CSTONE PHARMA-B行情,CSTONE PHARMA-B股票行情,CSTONE PHARMA-B股价,CSTONE PHARMA-B股市,CSTONE PHARMA-B股票价格,CSTONE PHARMA-B股票交易,CSTONE PHARMA-B股票购买,CSTONE PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}